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Introduction  
Cosci and Chouinard (1) present a very elegant and thought-provoking 
overview. They comment extensively on the potential possessed by a 
range of therapeutically prescribed, under appropriate medical control, 
psychotropics of being associated with a short-/long-term withdrawal 
syndrome when discontinued. This is a relevant clinical topic; indeed, in 
parallel with a decline in the UK of both benzodiazepines (BDZ) and Z-
drugs (e.g. zaleplon; zolpidem; zopiclone), a significant increase in 
antidepressants’; second generation antipsychotics’; and gabapentinoids’ 
prescriptions have been observed (2; 3).  
 
Recreational and prescribing psychotropics; terminology issues 
Recreational, abused drugs (e.g. cannabinoids; cocaine; MDMA/ecstasy) 
appear to increase dopaminergic signalling in ventral striatal regions, 
including the nucleus accumbens, a key site of the mesolimbic reward 
pathway (4; 5). Increased activity in striatal dopaminergic signalling 
pathways is likely associated with their subjective rewarding, euphoric 
and reinforcing effects of such molecules. Conversely, reduced 
dopaminergic transmission in the limbic system plays a role in drug 
craving; withdrawal; and relapse into compulsive drug intake (5). 
Furthermore, recreational drugs are considered to possess no, or very 
limited, therapeutic value. 
When referring to therapeutically prescribed molecules, however, there 
are levels of clinical terminology confusion (6). In fact, the related terms 
‘misuse’; ‘abuse’; ‘dependence’; and ‘addiction’ are often used in the 
literature without standardized definitions. From a pharmacovigilance (7) 
perspective, ‘misuse’ is the intentional and inappropriate use of a product 
other than as prescribed or not in accordance with the authorized product 
information, whilst ‘abuse’ is the intentional non-therapeutic use of a 
product for a perceived reward, including ‘getting high’/euphoria (8).  
Conversely, dependence is characterized ‘per se’ by tolerance and/or 
withdrawal symptoms (9), with ‘withdrawal’ however not necessarily 
including the occurrence of physical signs and symptoms (10). Finally, 
‘addiction’ is characterized by a further range of issues, e.g. compulsive 
substance use; cravings; and continued use despite its adverse 
consequences (6; 11-12). Hence, withdrawal symptoms that occur upon 
discontinuation of medications prescribed for valid medical reasons do not 
suggest, per se, either a substance-related (13) or an addiction disorder 
(6). This may well be the case with both antidepressants (ADs; 14-16) 
and benzodiazepines (BDZ; 17).  
Withdrawal, a more appropriate term than ‘discontinuation’ (18), 
syndromes occur with most recreational, and a range of prescribed, drugs 
(15). These syndromes may include the following features: a) rebound, 
e.g. the re-occurrence of the original symptoms for which the index 
medication was prescribed; b) withdrawal, including both rebound and 
new, unrelated, symptoms; and c) persistent post-withdrawal disorder, 
characterized by a return of higher severity original illness, often 
associated with additional features (1).  
Withdrawal syndromes have been interpreted in light of the concept of 
behavioural toxicity (1, 19-21). In 1968, Di Mascio and Shader (22) 
specifically addressed the behavioural toxicity of psychotropics. They 
referred to the pharmacological actions of a drug that, within the dose 
range in which it has been found to possess clinical utility, may produce a 
range of psychological and behavioural alterations, thus limiting the 
capacity of the individual or constituting a hazard to his/her well-being.  
Such a concept was revisited by Fava et al. (21) in 2016. It may thus be 
of interest to analyze these phenomena in a population where 
psychotropic drugs are clearly misused/abused to outline similarities and 
differences. 
 
High-dosage medications’ misuse/abuse; the psychonauts’ world 
In clinical psychiatry settings, the therapeutically prescribed medicines’ 
intentional misuse and abuse may well be an unusual observation. It is 
here argued, however, that these same prescribing molecules, when 
ingested by those with a substance abuse history; at largely supra-
therapeutic dosages (e.g. pregabalin; venlafaxine; quetiapine); and/or 
with modalities that increase their bioavailability (e.g. loperamide) may 
be associated with a clear cut ‘reward’ sensation. This is at odds with 
other reports, suggesting that medications’ misuse may be associated 
with only soothing effects, but little else (6).  
Indeed, a range of prescribed medications are currently being used 
recreationally, typically at high-/super-high dosages, as new/novel 
psychoactive substances (NPS; 23). Within both online drug forum 
communities and social networks, there are some educated/informed 
users (the ‘psychonauts’; 24) who are keen to ‘test’ a range of molecules, 
including prescribing psychotropics, to achieve specific mindsets. Their 
information is routinely being shared online (24) and vulnerable subjects, 
including both children/adolescents and psychiatric patients, may hence 
be at-risk of accessing these ‘pro drug’ data (25).  
Psychonauts are a clinical ‘niche’, and their idiosyncratic levels of 
medications’ intake are better scrutinized with the help of the 
netnographic research approach (26). This approach should be 
interpreted as a ‘magnifying lens’, aimed at shedding further light on the 
putative misuse; abuse; and dependence potential of those psychotropics 
being prescribed by practicing psychiatrists.  
The focus will be here on the different withdrawal; misuse; abuse; and 
dependence issues associated with the typically high-/very high-dosage 
recreational intake of a range of prescribed psychotropics, including: 
GABAergics; antidepressants; ketamine and related drugs; 
antipsychotics; gabapentinoids; and over-the-counter opiates/opioids. 
 
GABAergics (benzodiazepines; ‘Z-drugs’; GABA-A/GABA-B 
agonists) 
 
Prescribed and designer/’exotic’ benzodiazepines 
According to a recent EU-wide emergency department-admissions’ 
survey, the most frequently misused benzodiazepines were respectively 
clonazepam, diazepam, and alprazolam (27). In parallel with this, a range 
of NPS belonging to the BDZ class have recently appeared on the 
street/online/virtual markets and are known as ‘legal/exotic/designer’ 
benzodiazepines. Exotic BDZ were either tested, but not approved, as 
medicinal compounds or are derivatives of currently prescribed BDZ. For 
most of them, only very little pharmacology and toxicity knowledge is 
available (26). Most typically, online BDZ purchasers are per definition not 
aware if they are taking traditional; designer; or counterfeit BDZ. 
Although there are a few hundreds of exotic BDZ discussed within the 
NPS community (28), a non-participant, multilingual, 
qualitative/netnographic study recently focused on those 29 exotic BDZ 
which have been formally identified as NPS by the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) (26). They can be 
ingested, snorted or injected (29; for an overview of related clinical 
features, see Table 1). 
 
Z drugs 
Although sharing with benzodiazepines a similar mechanism of action, Z-
drugs appeared on the market as safe substitutes for benzodiazepines, 
purportedly having both a reduced abuse potential and propensity to 
induce less tolerance and withdrawal due to improved pharmacokinetics 
(30). Z-drugs’ withdrawal symptoms are similar to those observed with 
BDZ (see Table 1; 31). However, their idiosyncratic routes of 
administration and the high-dosage intake may well increase the risk of 
Z-drugs’ withdrawal issues (32).  
Schifano et al (33) analysed the Adverse Drug Reactions (ADR) datasets 
provided by the European Medicines Agency (EMA) through the 
EudraVigilance (EV) system. An overall total of 33,240 (e.g. 23,420 
zolpidem; 9,283 zopiclone; and 537 zaleplon) misuse/abuse/dependence 
and withdrawal-related ADRs, corresponding to some 6,246 unique 
patients, were identified. Out of these three molecules, zolpidem and 
zopiclone presented with the same dependence risk, but zolpidem was the 
most frequently associated with withdrawal issues. Zaleplon was the least 
reported for these ADRs (see Table 1). 
 
GHB/GBL 
Currently used in some countries to treat narcolepsy and alcohol 
withdrawal, gamma-hydroxybutyric acid (GHB; ‘liquid Ecstasy’) intake is 
associated with both increased central Dopamine levels and activation of 
GABA-A/B receptors (34). The GHB withdrawal syndrome has been well 
characterized (Table 1). In the UK, Corkery et al (34) described 159 
GHB/GBL-associated fatalities; most (79%) were accidental and GHB/GBL 
alone was implicated in 37% of cases. 
 
Phenibut 
Phenibut/’PB’ is openly available online as both a nootropic and a dietary 
supplement. When misused at high dosages (Table 1) it acts as an GABA-
A/B receptors’ agonist, whilst stimulating Dopamine/Serotonin 
neurotransmission as well. Its use may rapidly lead to dependence; 
withdrawal signs/symptoms may include visual and auditory 
hallucinations (29; Table 1) 
 
Baclofen 
Baclofen is a GABA-B agonist showing both anxiolytic and analgesic 
properties; the intake of high dosages is associated with euphoria, 
relaxation and anxiety blocking effects. Baclofen should always be 
withdrawn gradually (29; Table 1). 
 
Antidepressants (ADs) 
Out of all ADs, bupropion and venlafaxine have emerged as increasingly 
being misused and abused (35). Both high/very high (e.g. up to 4,050 
mg/day, roughly 14 times higher than the maximal therapeutic dosage 
with oral, nasal, and intravenous use) bupropion’s stimulant effects have 
been reported (Table 1), consistent with its action both as a selective 
inhibitor of Noradrenaline/NA and Dopamine/DA reuptake. Bupropion is a 
cathinone derivative, resembling the remaining large number of synthetic 
cathinones’ NPS (36).  Typical bupropion idiosyncratic dosage abusers 
may present with a history of drug addiction and/or are inmates (35; 37; 
Table 1). Even venlafaxine, at mega dosages, can be misused and abused 
(38; Table 1); this is consistent with desvenlafaxine, being an inhibitor of 
NA transporter activities, further increasing the rate of DA turnover in the 
prefrontal cortex (39). In line with these observations, both the last 
decade European Medicines Agency (EMA) and the UK-based Yellow Card 
Scheme pharmacovigilance adverse drug reactions (ADRs) data (40) 
showed that, in comparison with venlafaxine, bupropion may possess a 
higher stimulant-like recreational activity. Conversely, the occurrence of a 
withdrawal syndrome was confirmed to be a significant issue for 
venlafaxine-treated patients (40). 
 
Ketamine and related drugs  
Ketamine psychiatric prescribing is on the increase (41); and the UK 
National Institute of Clinical Excellence (NICE) is currently reviewing the 
possibility of its derivative esketamine being used for treatment-resistant 
depression. However, because of ketamine-related compounds’ associated 
psychosis and misuse, this decision has sparked levels of controversy 
(42). Ketamine acts as an N-methyl-D-aspartate (NMDA) receptor 
antagonist, whilst inhibiting both the voltage-gated Na/K channels; 
Serotonin; and DA reuptake. All these actions are likely contributing to 
both its significant psychoactive effects and addictive liability issues (43-
44; Table 1). The occurrence of ketamine-associated urinary dysfunction’s 
(45) painful symptoms can facilitate persistence in ketamine intake, 
because of its analgesic properties. There are a range of ketamine/‘special 
K’-related molecules being widely misused by psychonauts, including 
methoxetamine (‘special M’; 46) and dextromethorphan (DXM; ‘green 
triangle), an over-the-counter cough/cold remedy (29). 
 
Antipsychotics (quetiapine; olanzapine; clozapine) 
Commonly prescribed in the 400–800 mg/day range, quetiapine (‘Susie 
Q’; ‘Q ball’ and ‘Maq ball’ if respectively associated with cocaine and 
marijuana) appears to be the most documented antipsychotic being 
abused either on its own, or in combination (17). Its extended-release 
(XR) formulation may be less frequently misused and abused, due to the 
delayed (by approximately 3 h) and blunted (by approximately 67%) 
serum peak; the tablet coating may also make snorting of the crushed 
tablets quite problematic (47). Prison inmates and opioid addicts seem to 
represent the most at-risk populations. Quetiapine psychotropic effects 
are associated with both increased levels of DA in the nucleus accumbens 
(NAc) area (48) and D2 receptor blockade, although norquetiapine-related 
NA reuptake blockade; 5-HT7 antagonist properties; and sigma receptor 
activation; may contribute to its misuse liability (for a review, see 16).   
Conversely, olanzapine high-dosage has been anecdotally reported as the 
‘ideal trip terminator/modulator’ (49-50). These misusing liability levels 
may be associated with: olanzapine-related activity on GABA-A receptors, 
hence the associated sedation; the rewarding glutamatergic stimulation of 
the ventral tegmental area DAergic neurons; the 5HT2C and histamine/H1 
antagonist properties; and the potent inhibiting action on the muscarinic 
M1 receptors (for a review, see 35). 
All voluntary European Medicines Agency database reports relating to 
both quetiapine (2005-2016) and olanzapine (2004-2016) were 
recently analysed (34). From the EMA database, 18,112 (8.64% of 
209,571) and 4,178 (7.58% of 55,100) ADR reports of 
misuse/abuse/dependence and withdrawal were associated with 
quetiapine and olanzapine, respectively. The resulting proportional 
reporting ratio (PRR) values suggested that the withdrawal-related 
ADRs were more frequently reported for quetiapine, with a PRR=5.25, 
in comparison with olanzapine (51).  
Although clozapine is known to present with a range of well-known side-
effects, only anecdotal description is available relating to its putative 
withdrawal syndrome. Chiappini et al (52) recently analysed the 2005-
2018 EMA dataset of ADRs to identify and describe possible clozapine 
withdrawal-related issues. Out of 11,847 clozapine-related ADRs, some 
258 were withdrawal-related (52).  
 
Gabapentinoids 
Following initial reports from this Journal (53) the gabapentinoids 
pregabalin and gabapentin have been clearly identified as possessing a 
distinct potential for misuse (54). Chiappini and Schifano (55) aimed at 
assessing cases of gabapentinoid misuse or dependence as reported to 
the EMA EV database. All voluntary reports of both gabapentin-(2004–
2015) and pregabalin- (2006–2015) were retrieved. Some 7,639 (6.6 % 
of a total of 115,616) and 4,301 (4.8% of 90,166) ADR reports of 
misuse/abuse/dependence were, respectively, associated with pregabalin 
and gabapentin. Misuse/abuse/dependence-related entries were more 
frequently reported for pregabalin compared with gabapentin; frequent 
levels of co-ingestion with opiates/opioids was identified, especially in 
fatalities.  
Overall, gabapentinoids may induce a ‘liking’ (euphoric high) subjective 
feeling, but more limited levels of ‘wanting’/behavioural dependence (for 
an overview, see 56). Indeed, patients may report pleasant stimulation 
and euphoria only when using supratherapeutic/mega (e.g. 1,500‐12,000 
mg) pregabalin dosages (56). Hence, one could wonder if there may be a 
different/unclear range of neurotransmitter involvement, and receptors’ 




A massive, recent, worldwide increase in opiate/opioid prescription levels 
has been identified, with fentanyl being a reason of particular concern 
(57-59). Within the OTC abuse (‘pharming’) opiate/opioid scenario, the 
antidiarrhoeal loperamide has increasingly been reported by psychonauts 
as a recreational drug (60). Loperamide acts as a potent mu-opioid 
receptor agonist, albeit with predominantly peripheral activity on the 
myenteric plexus. Loperamide high-dosage ingestion has been associated 
with euphoria (60); different techniques are being used to increase its low 
bioavailability levels (35; 60; see Table 1). 
 
Conclusions 
The current editorial has taken inspiration from the thought-provoking 
Cosci and Chouinard (1) paper; they focussed on the withdrawal 
syndromes associated with a range of therapeutic dosage, medically 
prescribed, psychotropics’ intake. The issues associated with these same 
psychotropics, albeit ingested as advised by the psychonauts, have been 
described here.  
It is here suggested that when selected psychotropic medications are self-
administered at mega-, as opposed to therapeutic, dosage levels, the 
associated withdrawal; persistent post-withdrawal; and overall 
behavioural toxicity issues may be particularly relevant. Indeed, when 
tapering down a therapeutic dosage AD, symptoms most typically are 
both mild/go untreated; and resolve spontaneously (21). However, when 
high-/mega-dosage ADs (37; 61); gabapentinoids (62); or BDZ (26) are 
discontinued, the intense related withdrawal symptoms will always need 
proper, long-term, specialist attention. Second, the occurrence of a 
persistent post-withdrawal disorder is only occasionally observed with 
both antipsychotics (e.g. tardive dyskinesia and supersensitivity 
psychosis) and ADs (e.g. mood fluctuations; 16). Conversely, with high-
dosage medications (e.g. negative affect; dysphoria; and protracted 
insomnia for opiates/opioids; 63) is very frequently reported. Finally, the 
range of psychotropics’ intake-related behavioural toxicity syndromes 
which at therapeutic dosage are at times observed may include: 
alterations in mood, perceptual, cognitive and psychomotor functions 
(21), but also both ‘paradoxical’ (e.g. increased anxiety and rage, as 
opposed to sedation, with benzodiazepines) and ‘pendular’ drug effects 
(e.g. excessive/euphoric mood lifting modifications with ADs) (22). 
Conversely, at mega psychotropics’ dosages the range of the above 
clinical effects are being typically observed, indeed representing the 
sought-after effects. This is especially true for: venlafaxine (MDMA-like 
perceptual disturbances); bupropion (excessive mood lifting, pendular 
drug alterations; 64); pregabalin (perceptual disturbances/dissociative 
effects); and quetiapine (intense psychomotor function retardation 
effects). Further, the therapeutic dosage benzodiazepines’ intake may be 
associated with paradoxical effects only in selected, e.g. personality 
disorder (65) or elderly (66), patients’, subgroups. Conversely, the high-
dosage; highly potent; BDZ/novel BDZ are often ingested to achieve 
proper stimulant/aggressive, as opposed to sedative, effects (65; 67) 
Increasing levels of access to the web over the past 15 years or so may 
have contributed to the current scenario of prescribed drugs’ misuse and 
abuse, with social networks having played a role in prescription drugs’ 
aggressive marketing/distribution from rogue websites (25). However, 
one should here emphasize that, for most prescription molecules here 
discussed, including gabapentinoids, pre-marketing processes were not 
able to appropriately identify their misuse and abuse potential. Pre-
authorization trials however typically involve the administration of 
carefully controlled, daily limited, therapeutic dosages and subjects with a 
current/previous history of drug misuse are excluded (68). Hence, the 
molecule’s possible potential for abuse will be fully appreciated only when 
the real-world client population, involving vulnerable individuals, is 
exposed to it. Because of a likely post-marketing reporting bias (e.g. 
clinicians typically flagging only those molecules which have already been 
identified as at-risk for misuse and abuse), pharmacovigilance should 
identify a range of technical tools and approaches to go beyond voluntary 
reporting systems.   
At high-/very high- dosage, a range of medications including 
antidepressants, antipsychotics, and gabapentinoids can be self-
administered as proper drugs of abuse. Physicians should be vigilant 
when prescribing drugs with an abuse/misuse/diversion potential (69) and 
carefully evaluate the risk for some clients to be prone to ingest high-
/mega-dosage medications, often in combination with alcohol and illicit 
drugs. Prescribers should hence be aware of the possibility of feigning 
psychiatric symptoms in order to obtain specific medications (70).  
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Table 1: Acute intoxication; withdrawal; and clinical issues associated 
with a range of high-dosage, prescribing psychotropics’, intake 
Drug category Typical acute intoxication 
signs/symptoms 










































For phenazepam, the most 
well-known exotic molecule:  it 
can be ingested, snorted or 
injected; euphoric effects but 
also amnesia, drowsiness, 
dizziness, somnolence, 
difficulty in waking up, muscle 
weakness, headache, 
weakening of attention, 
incoordination, blurred vision, 
slurred speech, ataxia, and 
muscle weakness. At high 
dosages, delirium and 
psychosis-like behaviour (26; 
29 27)  
Similar to traditional BDZ, 
withdrawal, dependence and 
tolerance have been documented.  
The withdrawal syndrome may 
however be arguably more intense 
when abruptly discontinuing 
potent/very potent BDZ  
Alprazolam: 30 




















ingested at > 4 
mg (26) 
 
Pyrazolam is 12x   
more potent than 
diazepam; 





>8-12 mg (26) 
 
Meclonazepam: 
>1-2 mg (26) 
 
Flubromazolam: 
400-600 g is 
considered a very 
high dosage (24) 




Among Z-drugs, zolpidem is 
the most frequently misused 
and zaleplon the least; 
concomitant use of 
recreational drugs possible 
(33) 
 
Withdrawal signs/symptoms may 
include: insomnia, anxiety 
euphoria irritability, tremor, inner 
restlessness, speech difficulties, 
abdominal pain, hypertension, 










Euphoria and calmness are 
initially observed after 
ingestion. High dosages lead to 
drowsiness, nausea, vomiting, 
muscle stiffness, dizziness, 
confusion, delirium, 
hallucinations, convulsions and 
cardiopulmonary depression. 
Fatalities described (34). 
GHB is highly addictive; withdrawal 
syndrome: insomnia, muscular 
cramping, tremor and anxiety (29; 
34) 
GHB elimination 
half-life is 27 
minutes, hence 
the re-dosing 
risk; 10 mg/kg 
(0.75 g) is 






May rapidly lead to 
dependence/tolerance. Acute 
Withdrawal signs/symptoms may 
include: visual and auditory 
Taken orally in 
dosages (e.g., 1-
intoxication is characterized by 
tachycardia, visual 
hallucinations, tremor, nausea 
and vomiting; serotonin 
syndrome possible (29) 
hallucinations, psychomotor 
agitation, derealization, 
depersonalization, increased light 
and sound sensitivity, muscle 
pain/twitches, tachycardia, 
nausea, tremor and insomnia (29) 
3 g) notably 






Euphoria, relaxation and 
mood-lifting effects; 
resembling a high-dosage GHB 
and/or a pregabalin large 
dosage intake (10) 
 
Common presenting withdrawal 
features: muscular hyperactivity, 
hyperthermia, metabolic 
derangements, rhabdomyolysis, 
convulsions and delirium; 
hallucinosis possible (29) 
> 100 mg (29) 
Antidepressants Bupropion: amphetamine-like 
‘high’ at mega dosages; acute 






Venlafaxine: may mimic 
MDMA/ecstasy effects; 
stimulant properties have been 
described as well (40) 
 
Bupropion: elicits cocaine-like 
cues; when discontinued, cravings, 






Venlafaxine: withdrawal symptoms 
may include: nausea, depression, 
suicidal thoughts, disorientation, 
stomach cramps, panic attacks, 
sexual dysfunction, headaches and 
occasional psychotic symptoms. 
(40) 
 














mindset or an 
‘amphetamine-
like’ high (38) 




effects: dissociative state of 
mind; perceptual distortions; 
out-of-the-body (OBE) and 
near-death (NDE) experiences 
(46) 
Withdrawal symptoms may 
include: cravings; moderate-to-










250mg is a really 
high dose that 
can send you into 




considered to ‘come off the 
psychedelic trip’, and for the 
desire of ‘feeling mellow’ (47) 
 
Olanzapine: anecdotally 
reported as the ‘ideal trip 
terminator/modulator’ after a 
psychedelic drug binge. For 
those on methadone 
maintenance, olanzapine being 
used to ‘get stoned’ (49) 
Quetiapine withdrawal syndrome: 
anxiety; agitation; possibility of 
movement disorders and 

















Euphoric and dissociative 
effects; pregabalin perceived 
as an ‘ideal psychotropic drug’ 
to achieve specific mindsets, 
including relaxation and 
disinhibition (55)  
Withdrawal features: anxiety, 
insomnia, panic; suicidal ideation; 
chest pain, muscle weakness; 
possible dyspnoea, palpitations, 
and dizziness (55) 
Pregabalin: 
1,500‐12,000 mg  
 
Gabapentin: 




Loperamide ingestion has been 
associated with euphoria (‘lope 
dope’; ‘poors’ methadone’), 
central nervous system 
depression and even death, 
due to cardiac dysrhythmias 
(60) 
 
Opiate/opioid including loperamide 
withdrawal features: muscle 
aches; restlessness; anxiety; 
lacrimation; runny nose; excessive 
sweating; insomnia; yawning; 
diarrhoea; abdominal cramps; 
goose bumps on the skin; nausea 
and vomiting; dilated pupils; 
tachycardia and hypertension (59)  
Loperamide: 
doses of 50–
1,200 mg. To 
increase its low 
bioavailability 
levels, normally 
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